Related Experiment Video
Updated: Feb 11, 2026

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma
Published on: January 25, 2015
Chemotherapy Plus Bevacizumab as Neoadjuvant or Conversion Treatment in Patients with Colorectal Liver Metastases
Pilar García-Alfonso1, Mercedes Cavanagh Podesta2, Andrés Muñoz Martín2
1Department of Medical Oncology, Gregorio Marañon University General Hospital, Madrid, Spain pgarcaalfonso@gmail.com.
Aim:
To evaluate the efficacy of chemotherapy plus bevacizumab as neoadjuvant or conversion treatment for colorectal liver metastases (CLM).
Patients And Methods:
A retrospective chart review was carried out of 74 patients with CLM treated with neoadjuvant or conversion chemotherapy plus bevacizumab.
Results:
The overall response rate was 63.4%. An optimal morphological response by computed tomography was reported in 35% of patients. The rate of complete resection was 71.6%. Complete or major pathological response (pR) was attained in 58.2%. The median overall survival (OS) was not reached. Median progression-free (PFS) and relapse-free (RFS) survival were 14.6 and 8.7 months. Among patients reaching an optimal pR, median OS was not reached (p=0.08), and a trend towards longer RFS and PFS was seen.
Conclusion:
Neoadjuvant or conversion chemotherapy with bevacizumab is an active and tolerable option for CLM with minimal post-surgery complications. Optimal pR is associated with a longer OS and a trend for prolonged PFS and RFS.
More Related Videos
Related Concept Videos
Gene Conversion
Gene Conversion
Conversion of Units
The first step in the unit conversion is to list the given units and the units required...
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Two synthetic agonists of THC,...
Conversion of Alcohols to Alkyl Halides
Liver Histology
Hepatocytes perform a variety of essential functions. They secrete...

